FDA publish EUA guidance – condition of EUA “no alternatives” can be available

On January 13, 2017 following a PAHPRA amendment the FDA issued guidance for industry and stakeholders around Emergency Use Authorisation (EUA) of Medical Products.

It states in guidance, section B.1.d titled “no alternatives” that “[f]or FDA to issue an EUA, there must be no adequate, approved, and available alternative to the candidate product for diagnosing, preventing, or treating the disease or condition”

For COVID-19 vaccines to be eligible for EUA, the system had to discredit and suppress any early treatment options such as hydroxychloroquine and ivermectin. [1]

“Public health was built on an obsessive global vaccination policy, which ivermectin would have threatened”
says Dr Pierre Kory